Search

Your search keyword '"Caimi, Paolo F"' showing total 662 results
Start Over Author "Caimi, Paolo F"
662 results on '"Caimi, Paolo F"'

1. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

Author

Epperla, Narendranath, Huang, Ying, Cashen, Amanda F., Vaughn, John L., Hanel, Walter, Badar, Talha, Barta, Stefan K., Caimi, Paolo F., Sethi, Tarsheen K., Reddy, Nishitha, Karmali, Reem, Bello, Celeste, Chavez, Julio C., Kothari, Shalin K., Hernandez-Ilizaliturri, Francisco J., Svoboda, Jakub, Lansigan, Frederick, Glenn, Martha J., Cohen, Jonathon B., Sorge, Caryn, Christian, Beth, Herrera, Alex F., Hamadani, Mehdi, Costa, Luciano J., and Xavier, Ana C.

Published
2024
Full Text
View/download PDF

2. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Author

Smith, Mitchell R., Jegede, Opeyemi A., Martin, Peter, Till, Brian G., Parekh, Samir S., Yang, David T., Hsi, Eric D., Witzig, Thomas, Dave, Sandeep, Scott, David, Hanson, Curtis, Kostakoglu Shields, Lale, Abdel-Samad, Nizar, Casulo, Carla, Bartlett, Nancy L., Caimi, Paolo F., Al Baghdadi, Tareq, Blum, Kristie A., Romer, Mark D., Inwards, David J., Lerner, Rachel E., Wagner, Lynne I., Little, Richard F., Friedberg, Jonathan W., Leonard, John P., and Kahl, Brad S.

Published
2024
Full Text
View/download PDF

3. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Author

Brem, Elizabeth A, Li, Hongli, Beaven, Anne W, Caimi, Paolo F, Cerchietti, Leandro, Alizadeh, Ash A, Olin, Rebecca, Henry, N Lynn, Dillon, Hildy, Little, Richard F, Laubach, Cara, LeBlanc, Michael, Friedberg, Jonathan W, and Smith, Sonali M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Hematology, Lymphoma, Clinical Trials and Supportive Activities, Aging, Rare Diseases, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Frailty, Humans, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Prospective Studies, Rituximab, DLBCL, Geriatric, Older, ctDNA, Oncology and carcinogenesis
Abstract

Diffuse large B cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy; however, cure is highly dependent on the ability to deliver intensive, anthracycline-based chemoimmunotherapy. Nearly one third of cases of DLBCL occur in patients over age 75 years, and advanced age is an important adverse feature in prognostic models. Despite this incidence in older patients, there is no clear accepted standard of care due to under-representation of this group in large randomized clinical trials. Furthermore, insufficient assessments of baseline frailty and prediction of toxicity hamper clinical decision-making. Here, we present an ongoing randomized study of R-miniCHOP chemoimmunotherapy with or without oral azacitidine (CC-486, Onureg) for patients age 75 and older with newly diagnosed DLBCL and associated aggressive lymphomas. The incorporation of an oral hypomethylating agent is based on increased tumor methylation as a biologic feature of older patients with DLBCL and a desire to minimize the injection burden for this population. This is the first randomized study in this population conducted in North America by the National Clinical Trials Network (NCTN) and will enroll up to 422 patients including 40 patients in a safety run-in phase. This study incorporates an objective assessment of baseline frailty (the FIL Tool) and a serial comprehensive geriatric assessment (CGA). Key correlative tests will include circulating tumor DNA (ctDNA) assays at pre-specified timepoints to explore if ctDNA quantity and methylation patterns correlate with response. S1918 has the potential to impact future trial design and to change the standard of care for patients 75 years and older with aggressive lymphoma given its randomized design, prospective incorporation of geriatric assessments, and exploration of ctDNA correlatives. Trial registration: The trial is registered with ClinicalTrial.gov Identifier NCT04799275.

Published
2022

4. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

Author

Metheny, Leland L., Sobecks, Ronald, Cho, Christina, Fu, Pingfu, Margevicius, Seunghee, Wang, Jiasheng, Ciarrone, Lisa, Kopp, Shelby, Convents, Robin D., Majhail, Navneet, Caimi, Paolo F., Otegbeye, Folashade, Cooper, Brenda W., Gallogly, Molly, Malek, Ehsan, Tomlinson, Benjamin, Gerds, Aaron T., Hamilton, Betty, Giralt, Sergio, Perales, Miguel-Angel, and de Lima, Marcos

Published
2024
Full Text
View/download PDF

8. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Author

Gerson, James N., Handorf, Elizabeth, Villa, Diego, Gerrie, Alina S., Chapani, Parv, Li, Shaoying, Medeiros, L. Jeffrey, Wang, Michael, Cohen, Jonathon B., Churnetski, Michael, Hill, Brian T., Sawalha, Yazeed, Hernandez-Ilizaliturri, Francisco J., Kothari, Shalin, Vose, Julie M., Bast, Martin, Fenske, Timothy, Rao Gari, Swapna Narayana, Maddocks, Kami J., Bond, David, Bachanova, Veronika, Kolla, Bhaskar, Chavez, Julio, Shah, Bijal, Lansigan, Frederick, Burns, Timothy, Donovan, Alexandra M., Wagner-Johnston, Nina, Messmer, Marcus, Mehta, Amitkumar, Anderson, Jennifer K., Reddy, Nishitha, Kovach, Alexandra E., Landsburg, Daniel J., Glenn, Martha, Inwards, David J., Ristow, Kay, Karmali, Reem, Kaplan, Jason B., Caimi, Paolo F., Rajguru, Saurabh, Evens, Andrew, Klein, Andreas, Umyarova, Elvira, Pulluri, Bhargavi, Amengual, Jennifer E., Lue, Jennifer K., Diefenbach, Catherine, Fisher, Richard I., and Barta, Stefan K.

Published
2023
Full Text
View/download PDF

13. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice.

Author

Grégoire, Céline, Coutinho de Oliveira, Beatriz, Caimi, Paolo F., Caers, Jo, and Melenhorst, Jan Joseph

Subjects
CHIMERIC antigen receptors, T cells, MULTIPLE myeloma, ACUTE leukemia, TREATMENT failure
Abstract

Summary: Autologous chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of lymphoid malignancies, leading to the approval of CD19‐CAR T cells for B‐cell lymphomas and acute leukaemia, and more recently, B‐cell maturation antigen‐CAR T cells for multiple myeloma. The long‐term follow‐up of patients treated in the early clinical trials demonstrates the possibility for long‐term remission, suggesting a cure. This is associated with a low incidence of significant long‐term side effects and a rapid improvement in the quality of life for responders. In contrast, other types of immunotherapies require prolonged treatments or carry the risk of long‐term side effects impairing the quality of life. Despite impressive results, some patients still experience treatment failure or ultimately relapse, underscoring the imperative to improve CAR T‐cell therapies and gain a better understanding of their determinants of efficacy to maximize positive outcomes. While the next‐generation of CAR T cells will undoubtingly be more potent, there are already opportunities for optimization when utilizing the currently available CAR T cells. This review article aims to summarize the current evidence from clinical, translational and fundamental research, providing clinicians with insights to enhance their understanding and use of CAR T cells. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Author

Orellana-Noia, Victor Manuel, Reed, Daniel R., McCook, Ashley Alesia, Sen, Jeremy Michael, Barlow, Christian M., Malecek, Mary-Kate, Watkins, Marcus, Kahl, Brad S., Spinner, Michael A., Advani, Ranjana, Voorhees, Timothy J., Snow, Anson, Grover, Natalie Sophia, Ayers, Amy, Romancik, Jason, Liu, Yuxin, Huntington, Scott F., Chavez, Julio C., Saeed, Hayder, Lazaryan, Aleksandr, Raghunathan, Vikram, Spurgeon, Stephen E., Ollila, Thomas A., Del Prete, Christopher, Olszewski, Adam, Ayers, Emily C., Landsburg, Daniel J., Echalier, Benjamin, Lee, Jun, Kamdar, Manali, Caimi, Paolo F., Fu, Timothy, Liu, Jieqi, David, Kevin A., Alharthy, Hanan, Law, Jennie, Karmali, Reem, Shah, Harsh, Stephens, Deborah M., Major, Ajay, Rojek, Alexandra E., Smith, Sonali M., Yellala, Amulya, Kallam, Avyakta, Nakhoda, Shazi, Khan, Nadia, Sohail, Mohammad Ahsan, Hill, Brian T., Barrett-Campbell, Odeth, Lansigan, Frederick, Switchenko, Jeffrey, Cohen, Jonathon, and Portell, Craig A.

Published
2022
Full Text
View/download PDF

15. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Author

Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M., Vermaat, Joost S.P., Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F., Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G., and Goy, Andre

Published
2022
Full Text
View/download PDF

16. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2022
Full Text
View/download PDF

17. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy

Author

Tarantelli, Chiara, primary, Wald, David, additional, Munz, Nicolas, additional, Spriano, Filippo, additional, Bruscaggin, Alessio, additional, Cannas, Eleonora, additional, Cascione, Luciano, additional, Gaudio, Eugenio, additional, Arribas, Alberto J., additional, Manjappa, Shivaprasad, additional, Golino, Gaetanina, additional, Scalise, Lorenzo, additional, Cacciapuoti, Maria Teresa, additional, Zucca, Emanuele, additional, Stathis, Anastasios, additional, Inghirami, Giorgio, additional, Van Berkel, Patrick H., additional, Rossi, Davide, additional, Caimi, Paolo F., additional, Zammarchi, Francesca, additional, and Bertoni, Francesco, additional

Published
2024
Full Text
View/download PDF

19. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Author

Davids, Matthew S., O'Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., and Flinn, Ian W.

Published
2021
Full Text
View/download PDF

23. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Author

Hamadani, Mehdi, primary, Spira, Alexander, additional, Zhou, Xiaolei, additional, Liao, Laura, additional, Chen, Lei, additional, Radford, John, additional, Ai, Weiyun, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian, additional, Caimi, Paolo F., additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Alderuccio, Juan Pablo, additional, Kahl, Brad, additional, Wang, Ying, additional, Qin, Yajuan, additional, Xu, Zhiying Cindy, additional, and Zinzani, Pier Luigi, additional

Published
2024
Full Text
View/download PDF

24. Supplementary Table S4 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

25. Data from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

26. Supplementary Figure S2 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

27. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

Author

Shapiro, Geoffrey I., LoRusso, Patricia, Dowlati, Afshin, T. Do, Khanh, Jacobson, Caron A., Vaishampayan, Ulka, Weise, Amy, Caimi, Paolo F., Eder, Joseph Paul, French, Christopher A., Labriola-Tompkins, Emily, Boisserie, Frédéric, Pierceall, William E., Zhi, Jianguo, Passe, Sharon, DeMario, Mark, Kornacker, Martin, and Armand, Philippe

Published
2021
Full Text
View/download PDF

28. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Author

Maschan, Michael, Caimi, Paolo F., Reese-Koc, Jane, Sanchez, Gabriela Pacheco, Sharma, Ashish A., Molostova, Olga, Shelikhova, Larisa, Pershin, Dmitriy, Stepanov, Alexey, Muzalevskii, Yakov, Suzart, Vinicius G., Otegbeye, Folashade, Wald, David, Xiong, Ying, Wu, Darong, Knight, Adam, Oparaocha, Ibe, Ferencz, Beatrix, Roy, Andre, Worden, Andrew, Kruger, Winfried, Kadan, Michael, Schneider, Dina, Orentas, Rimas, Sekaly, Rafick-Pierre, de Lima, Marcos, and Dropulić, Boro

Published
2021
Full Text
View/download PDF

29. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia

Author

Covut, Fahrettin, Gupta, Divya, Pinto, Raisa, Dambrosio, Nina, El Jurdi, Najla, Meyerson, Howard, Ueda, Masumi, Kolk, Merle, Creger, Richard, Metheny, Leland, Cooper, Brenda W., Caimi, Paolo F., Malek, Ehsan, Otegbeye, Folashade, Lazarus, Hillard M., De Lima, Marcos, and Tomlinson, Benjamin K.

Published
2019
Full Text
View/download PDF

30. BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation.

Author

Stuver, Robert, Mian, Agrima, Brown, Samantha, Devlin, Sean, Caimi, Paolo F., Chinapen, Stephanie, Dahi, Parastoo, Dean, Robert, Epstein‐Peterson, Zachary D., Hill, Brian, Horwitz, Steven M., Lahoud, Oscar, Lin, Richard, Moskowitz, Alison J., Sauter, Craig, Shah, Gunjan, Winter, Alison, Jagadeesh, Deepa, and Scordo, Michael

Published
2024
Full Text
View/download PDF

31. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Hamadani, Mehdi, additional, Nachiappan, Muthiah, additional, Leslom, Salman, additional, Kahl, Brad S., additional, Ai, Weiyun Z., additional, Radford, John, additional, Solh, Melhem, additional, Ardeshna, Kirit M., additional, Hess, Brian T., additional, Lunning, Matthew A., additional, Zinzani, Pier Luigi, additional, Stathis, Anastasios, additional, Carlo-Stella, Carmelo, additional, Lossos, Izidore S., additional, Caimi, Paolo F., additional, Han, Sunwoo, additional, Yang, Fei, additional, Kuker, Russ A., additional, and Moskowitz, Craig H., additional

Published
2023
Full Text
View/download PDF

32. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Author

Zelenetz, Andrew D., primary, Gordon, Leo I., additional, Abramson, Jeremy S., additional, Advani, Ranjana H., additional, Andreadis, Babis, additional, Bartlett, Nancy L., additional, Budde, L. Elizabeth, additional, Caimi, Paolo F., additional, Chang, Julie E., additional, Christian, Beth, additional, DeVos, Sven, additional, Dholaria, Bhagirathbhai, additional, Fayad, Luis E., additional, Habermann, Thomas M., additional, Hamid, Muhammad Saad, additional, Hernandez-Ilizaliturri, Francisco, additional, Hu, Boyu, additional, Kaminski, Mark S., additional, Karimi, Yasmin, additional, Kelsey, Christopher R., additional, King, Rebecca, additional, Krivacic, Susan, additional, LaCasce, Ann S., additional, Lim, Megan, additional, Messmer, Marcus, additional, Narkhede, Mayur, additional, Rabinovitch, Rachel, additional, Ramakrishnan, Praveen, additional, Reid, Erin, additional, Roberts, Kenneth B., additional, Saeed, Hayder, additional, Smith, Stephen D., additional, Svoboda, Jakub, additional, Swinnen, Lode J., additional, Tuscano, Joseph, additional, Vose, Julie M., additional, Dwyer, Mary A., additional, and Sundar, Hema, additional

Published
2023
Full Text
View/download PDF

34. Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation

Author

Ali, Naveed, Sharma, Ashish Arunkumar, de Rezende, Ana Carolina Pires, Otegbeye, Folashade, Latif, Bilal Muhammad, Kerbauy, Mariana Nassif, Cooper, Brenda W., Sanchez, Gabriela, Metheny, Leland, Bal, Saswat K., Sakuraba, Roberto, Tomlinson, Benjamin K., Boughan, Kirsten M., Kerbauy, Lucila, Malek, Ehsan, Ribeiro, Andreza Feitosa, Gallogly, Molly, Mansur, David, Pereira, Gisele, Weltman, Eduardo, Sekaly, Rafick-Pierre, de Lima, Marcos, Caimi, Paolo F., and Hamerschlak, Nelson

Published
2022
Full Text
View/download PDF

35. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study

Author

Kharfan-Dabaja, Mohamed A., Raj, Renju, Nikolaenko, Liana, Ahmed, Sairah, Reddy, Nishitha, Nathan, Sunita, Cherry, Mohamad, El-Jurdi, Najla, Obiozor, Cynthia, Fenske, Timothy S., Song, Joo, Muzzafar, Tariq, Ayala, Ernesto, Savani, Bipin, Khawandanah, Mohamad, Caimi, Paolo F., Hamadani, Mehdi, Forman, Stephen J., Hussaini, Mohamad, de Lima, Marcos, Olteanu, Horatiu, Shah, Bijal, Chavez, Julio C., Al Malki, Monzr, Kumar, Ambuj, and Ganguly, Siddhartha

Published
2018
Full Text
View/download PDF

37. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study

Author

Caimi, Paolo F., primary, Ai, Weiyun Z., additional, Alderuccio, Juan Pablo, additional, Ardeshna, Kirit M., additional, Hamadani, Mehdi, additional, Hess, Brian, additional, Kahl, Brad S., additional, Radford, John, additional, Solh, Melhem, additional, Stathis, Anastasios, additional, Zinzani, Pier Luigi, additional, Wang, Ying, additional, Qin, Yajuan, additional, Wang, Luqiang, additional, Xu, Zhiying Cindy, additional, and Carlo-Stella, Carmelo, additional

Published
2023
Full Text
View/download PDF

38. Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

Author

Tarantelli, Chiara, primary, Wald, David, additional, Munz, Nicolas, additional, Spriano, Filippo, additional, Bruscaggin, Alessio, additional, Cannas, Eleonora, additional, Cascione, Luciano, additional, Gaudio, Eugenio, additional, Arribas, Alberto J., additional, Manjappa, Shivaprasad, additional, Golino, Gaetanina, additional, Scalise, Lorenzo, additional, Zucca, Emanuele, additional, Stathis, Anastasios, additional, Van Berkel, Patrick H., additional, Rossi, Davide, additional, Caimi, Paolo F., additional, Zammarchi, Francesca, additional, and Bertoni, Francesco, additional

Published
2023
Full Text
View/download PDF

39. P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Author

Caimi, Paolo F, primary, Ai, Weiyun Z, additional, Pablo Alderuccio, Juan, additional, Ardeshna, Kirit M, additional, Hamadani, Mehdi, additional, Hess, Brian, additional, Kahl, Brad S, additional, Radford, John, additional, Solh, Melhem, additional, Stathis, Anastasios, additional, Luigi Zinzani, Pier, additional, Wang, Ying, additional, Qin, Yajuan, additional, Wang, Luqiang, additional, Xu, Cindy, additional, and Carlo-Stella, Carmelo, additional

Published
2023
Full Text
View/download PDF

40. Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells

Author

Zeng, Ke, primary, Huang, Meixian, additional, Lyu, Mi-Ae, additional, Khoury, Joseph D., additional, Ahmed, Sairah, additional, Patel, Krina K., additional, Dropulić, Boro, additional, Reese-Koc, Jane, additional, Caimi, Paolo F., additional, Sadeghi, Tara, additional, Lima, Marcos de, additional, Flowers, Christopher R., additional, and Parmar, Simrit, additional

Published
2023
Full Text
View/download PDF

45. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐ H odgkin lymphoma: A phase I/ II study

Author

Vose, Julie M., primary, Ganguly, Siddhartha, additional, Bierman, Philip J., additional, Bociek, R. Gregory, additional, Lunning, Matthew, additional, Lyden, Liz, additional, Meza, Jane L., additional, Caimi, Paolo F., additional, and Armitage, James O., additional

Published
2023
Full Text
View/download PDF

46. Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)

Author

Palomba, Maria Lia, primary, Mei, Matthew G., additional, Caimi, Paolo F., additional, Cortese, Matthew, additional, Davila, Marco, additional, Yadnik, Greg, additional, Huang, Nestor, additional, Mou, David, additional, Oft, Martin, additional, Aspuria, Paul-Joseph, additional, Mehta-Damani, Anita, additional, Ratti, Navneet, additional, Rizvi, Naiyer, additional, Azrilevich, Alex, additional, and Reshef, Ran, additional

Published
2023
Full Text
View/download PDF

47. Data from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma

Author

Jackson, Zachary, primary, Hong, Changjin, primary, Schauner, Robert, primary, Dropulic, Boro, primary, Caimi, Paolo F., primary, de Lima, Marcos, primary, Giraudo, Maria Florencia, primary, Gupta, Kalpana, primary, Reese, Jane S., primary, Hwang, Tae Hyun, primary, and Wald, David N., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma

Author

Jackson, Zachary, primary, Hong, Changjin, primary, Schauner, Robert, primary, Dropulic, Boro, primary, Caimi, Paolo F., primary, de Lima, Marcos, primary, Giraudo, Maria Florencia, primary, Gupta, Kalpana, primary, Reese, Jane S., primary, Hwang, Tae Hyun, primary, and Wald, David N., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Data from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma

Author

Jackson, Zachary, primary, Hong, Changjin, primary, Schauner, Robert, primary, Dropulic, Boro, primary, Caimi, Paolo F., primary, de Lima, Marcos, primary, Giraudo, Maria Florencia, primary, Gupta, Kalpana, primary, Reese, Jane S., primary, Hwang, Tae Hyun, primary, and Wald, David N., primary

Published
2023
Full Text
View/download PDF

50. Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., Shouse, Geoffrey, Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results